Federica Bellone, Carmela Morace, Giulia Impalà, Anna Viola, Alberto Lo Gullo, Maria Cinquegrani, Walter Fries, Alberto Sardella, Mariangela Scolaro, Giorgio Basile, Giovanni Squadrito, Giuseppe Mandraffino
BACKGROUND: Inflammatory bowel diseases (IBDs), including ulcerative colitis (UC) and Crohn's disease (CD), are chronic and disabling diseases that affect patient health-related quality of life (HRQoL). IBD patients are frequently exposed to high levels of stress and psychological distress. Biological drugs have been proven to reduce inflammation, hospitalization, and most of the complications that characterize IBDs; their potential contribution to patients' HRQoL remains to be explored...
June 2, 2023: Journal of Personalized Medicine